• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

    5/4/23 4:10:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDF alert in real time by email

    First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC)

    Introduced full membership of Scientific Advisory Board (SAB)

    Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

    Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025

    SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-quarter ended March 31, 2023, and provided a business update.

    Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (PRNewsfoto/Cardiff Oncology, Inc.)

    "We are delighted to have dosed the first patient in our Phase 2 ONSEMBLE trial. This randomized trial will evaluate the efficacy of onvansertib combined with standard of care in patients with KRAS/NRAS-mutated mCRC, who historically have limited treatment options," said Mark Erlander, PhD, Chief Executive Officer of Cardiff Oncology. "In addition, we are excited to have appointed Fairooz Kabbinavar, MD, FACP, as our new Chief Medical Officer, who brings deep expertise in the treatment of patients with CRC as well as expertise in using bevacizumab in the clinical setting. We believe Dr. Kabbinavar adds significant value to our clinical development program for onvansertib. We also formally introduced the full membership of our Scientific Advisory Board, a group of highly esteemed oncology experts who are providing a diverse range of insights that strengthen our clinical programs."

    Upcoming potential milestones

    • Metastatic pancreatic ductal adenocarcinoma (mPDAC) data readout from Phase 2 trial expected in mid-2023
    • Small cell lung cancer (SCLC) data readout from investigator-initiated (with UPMC) Phase 2 trial expected in mid-2023
    • Triple negative breast cancer (TNBC) data readout from investigator-initiated (with Dana-Farber Cancer Institute) Phase 1b/2 trial expected in the fourth-quarter of 2023 or first-quarter of 2024
    • mCRC randomized data readout from Phase 2 ONSEMBLE trial expected in the second-half of 2024

    Company Highlights for the quarter ended March 31, 2023

    • Announced the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer. Dr. Kabbinavar oversees the clinical development program for the Company's investigational drug onvansertib and reports directly to Chief Executive Officer, Mark Erlander, PhD.
    • Formally introduced the full membership of its Scientific Advisory Board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who bring depth and breadth of knowledge in oncology drug development, clinical trial design, translational science and clinical research. In most cases, these individuals have been advising the Company for several years and will now collectively serve a critical role as we advance the clinical development of onvansertib. The Company anticipates that over time the membership of the SAB may expand to add additional expertise in new indications or stages of clinical development.
    • Announced First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer. The Phase 2 ONSEMBLE trial includes patients with mCRC who have a documented KRAS or NRAS mutation and have previously received one prior chemotherapy regimen with or without bevacizumab in the first line metastatic setting. Patients are being randomized to onvansertib plus FOLFIRI/bevacizumab versus FOLFIRI/bevacizumab (standard of care).

    First-Quarter 2023 Financial Results

    Liquidity, cash burn, and cash runway

    As of March 31, 2023, Cardiff Oncology had approximately $97.0 million in cash, cash equivalents, and short-term investments.

    Net cash used in operating activities for the first quarter of 2023 was approximately $8.7 million, a decrease of approximately $1.5 million from $10.2 million for the same period in 2022.

    Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025.

    Operating results

    Total operating expenses were approximately $12.1 million for the three months ended March 31 2023, an increase of $1.0 million from $11.1 million for the same period in 2022. The increase in operating expenses was primarily due to higher costs associated with clinical programs and outside service costs related to the development of the company's lead drug candidate, salaries and staff costs primarily due to increased headcount.

    About Cardiff Oncology, Inc.

    Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

    Cardiff Oncology Contact:

    James Levine 

    Chief Financial Officer 

    858-952-7670 

    [email protected] 

    Investor Contact:  

    Kiki Patel, PharmD  

    Gilmartin Group 

    332-895-3225

    [email protected] 

    Media Contact:  

    Richa Kumari 

    Taft Communications 

    551 344-5592  

    [email protected] 

     

    Cardiff Oncology, Inc.

    Condensed Statements of Operations

    (in thousands, except for per share amounts)

    (unaudited)





    Three Months Ended March 31,



    2023



    2022

    Royalty revenues

    $                   83



    $                   74

    Costs and expenses:







    Research and development

    9,052



    7,208

    Selling, general and administrative

    3,083



    3,940

    Total operating expenses

    12,135



    11,148









    Loss from operations

    (12,052)



    (11,074)









    Interest income, net

    940



    130

    Other income (expense), net

    (111)



    (49)

    Net loss

    (11,223)



    (10,993)

    Preferred stock dividend

    (6)



    (6)

    Net loss attributable to common stockholders

    $          (11,229)



    $          (10,999)









    Net loss per common share — basic and diluted

    $              (0.25)



    $              (0.25)









    Weighted-average shares outstanding — basic and diluted

    44,677



    43,231

     

    Cardiff Oncology, Inc.

    Condensed Balance Sheets

    (in thousands)

    (unaudited)





    March 31, 2023



    December 31, 2022

    Assets







    Current assets:







    Cash and cash equivalents

    $                  15,017



    $                  16,347

    Short-term investments

    81,951



    88,920

    Accounts receivable and unbilled receivable

    676



    771

    Prepaid expenses and other current assets

    4,109



    5,246

    Total current assets

    101,753



    111,284

    Property and equipment, net

    1,320



    1,269

    Operating lease right-of-use assets

    2,115



    2,251

    Other assets

    1,361



    1,387

    Total Assets

    $                106,549



    $                116,191









    Liabilities and Stockholders' Equity







    Current liabilities:







    Accounts payable

    $                     2,914



    $                     1,956

    Accrued liabilities

    4,555



    5,177

    Operating lease liabilities

    679



    675

    Total current liabilities

    8,148



    7,808

    Operating lease liabilities, net of current portion

    1,898



    2,040

    Total Liabilities

    10,046



    9,848









    Stockholders' equity

    96,503



    106,343

    Total liabilities and stockholders' equity

    $                106,549



    $                116,191

     

    Cardiff Oncology, Inc.

    Condensed Statements of Cash Flows

    (in thousands)

    (unaudited)





    Three Months Ended March 31,



    2023



    2022

    Operating activities







    Net loss

    $          (11,223)



    $          (10,993)

    Adjustments to reconcile net loss to net cash used in operating activities:







    Depreciation

    90



    31

    Stock-based compensation expense

    1,064



    1,152

    Amortization of premiums on short-term investments

    (163)



    346

    Release of clinical trial funding commitment

    —



    139

    Changes in operating assets and liabilities

    1,573



    (924)

    Net cash used in operating activities

    (8,659)



    (10,249)









    Investing activities:







    Capital expenditures

    (8)



    (171)

    Net purchases, maturities and sales of short-term investments

    7,337



    18,529

    Net cash provided by investing activities

    7,329



    18,358









    Financing activities:







    Net cash provided by financing activities

    —



    —

    Net change in cash and cash equivalents

    (1,330)



    8,109

    Cash and cash equivalents—Beginning of period

    16,347



    11,943

    Cash and cash equivalents—End of period

    $           15,017



    $           20,052

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-reports-first-quarter-2023-results-and-provides-business-update-301816420.html

    SOURCE Cardiff Oncology, Inc.

    Get the next $CRDF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRDF

    DatePrice TargetRatingAnalyst
    6/24/2025$3.50Hold
    Jefferies
    9/6/2024$8.00Buy
    Craig Hallum
    2/28/2022$26.00 → $25.00Buy
    HC Wainwright & Co.
    1/5/2022Outperform
    William Blair
    12/8/2021$19.00Outperform
    Robert W. Baird
    12/8/2021$19.00Outperform
    Baird
    8/10/2021$25.00 → $26.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $20.00Buy
    Maxim Group
    More analyst ratings

    $CRDF
    SEC Filings

    See more
    • Cardiff Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      6/26/25 4:30:47 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      6/17/25 4:15:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Cardiff Oncology Inc.

      EFFECT - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/14/25 12:15:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

      – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") – SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announc

      6/17/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

      – Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxicity profile – SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive data from an investigator-initiated Phase 1b cli

      6/2/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/18/24 4:37:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/16/24 5:00:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/12/24 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Tannenbaum Renee P

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:39:52 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Markin Rodney S

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:38:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mohindru Mani

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:38:05 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Cardiff Oncology with a new price target

      Jefferies initiated coverage of Cardiff Oncology with a rating of Hold and set a new price target of $3.50

      6/24/25 8:00:04 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum initiated coverage on Cardiff Oncology with a new price target

      Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00

      9/6/24 7:59:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously

      2/28/22 7:10:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

      First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

      5/4/23 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

      Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

      2/2/23 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

      SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in

      1/11/22 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Financials

    Live finance-specific insights

    See more
    • Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

      – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") – SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announc

      6/17/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

      SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors

      2/20/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/6/24 4:01:34 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/14/23 12:47:09 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cardiff Oncology Inc.

      SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)

      1/26/23 1:30:22 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care